{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:12:25Z","timestamp":1792419145813,"version":"4.5.0"},"reference-count":82,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["329628492"],"award-info":[{"award-number":["329628492"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["FU 356\/12-2"],"award-info":[{"award-number":["FU 356\/12-2"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["031L0305A"],"award-info":[{"award-number":["031L0305A"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KD2206A\/SATURN3"],"award-info":[{"award-number":["01KD2206A\/SATURN3"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019180","name":"EC | ERC | HORIZON EUROPE European Research Council","doi-asserted-by":"publisher","award":["833710"],"award-info":[{"award-number":["833710"]}],"id":[{"id":"10.13039\/100019180","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Syst Biol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The DNA-damaging agent Gemcitabine (GEM) is a first-line treatment for pancreatic cancer, but chemoresistance is frequently observed. Several clinical trials investigate the efficacy of GEM in combination with targeted drugs, including kinase inhibitors, but the experimental evidence for such rationale is often unclear. Here, we phenotypically screened 13 human pancreatic adenocarcinoma (PDAC) cell lines against GEM in combination with 146 clinical inhibitors and observed strong synergy for the ATR kinase inhibitor Elimusertib in most cell lines. Dose-dependent phosphoproteome profiling of four ATR inhibitors following DNA damage induction by GEM revealed a strong block of the DNA damage response pathway, including phosphorylated pS468 of CHEK1, as the underlying mechanism of drug synergy. The current work provides a strong rationale for why the combination of GEM and ATR inhibition may be useful for the treatment of PDAC patients and constitutes a rich phenotypic and molecular resource for further investigating effective drug combinations.<\/jats:p>","DOI":"10.1038\/s44320-025-00085-6","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T11:14:57Z","timestamp":1737458097000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Gemcitabine and ATR inhibitors synergize to kill PDAC cells by blocking DNA damage response"],"prefix":"10.1038","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0489-6854","authenticated-orcid":false,"given":"Stefanie","family":"H\u00f6fer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-1529-7341","authenticated-orcid":false,"given":"Larissa","family":"Frasch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Brajkovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8375-5908","authenticated-orcid":false,"given":"Kerstin","family":"Putzker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joe","family":"Lewis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8195-4396","authenticated-orcid":false,"given":"Hendrik","family":"Sch\u00fcrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Leone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Sakhteman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5401-5553","authenticated-orcid":false,"given":"Matthew","family":"The","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian P","family":"Bayer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4108-7926","authenticated-orcid":false,"given":"Julian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Firas","family":"Hamood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8772-4778","authenticated-orcid":false,"given":"Jens T","family":"Siveke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8611-5639","authenticated-orcid":false,"given":"Maximilian","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9094-1677","authenticated-orcid":false,"given":"Bernhard","family":"Kuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,21]]},"reference":[{"key":"85_CR1","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/COC.0000000000000633","volume":"43","author":"RA Abrams","year":"2020","unstructured":"Abrams RA, Winter KA, Safran H, Goodman KA, Regine WF, Berger AC, Gillin MT, Philip PA, Lowy AM, Wu A et al (2020) Results of the NRG oncology\/RTOG 0848 adjuvant chemotherapy question-erlotinib+gemcitabine for resected cancer of the pancreatic head: a phase II randomized clinical trial. Am J Clin Oncol 43:173\u2013179","journal-title":"Am J Clin Oncol"},{"key":"85_CR2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.7150\/jca.2.435","volume":"2","author":"C Bartholomeusz","year":"2011","unstructured":"Bartholomeusz C, Yamasaki F, Saso H, Kurisu K, Hortobagyi GN, Ueno NT (2011) Gemcitabine overcomes erlotinib resistance in EGFR-overexpressing cancer cells through downregulation of akt. J Cancer 2:435\u2013442","journal-title":"J Cancer"},{"key":"85_CR3","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-43696-z","volume":"14","author":"FP Bayer","year":"2023","unstructured":"Bayer FP, Gander M, Kuster B, The M (2023) CurveCurator: a recalibrated F-statistic to assess, classify, and explore significance of dose-response curves. Nat Commun 14:7902","journal-title":"Nat Commun"},{"key":"85_CR4","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc: Ser B (Methodol) 57:289\u2013300","journal-title":"J R Stat Soc: Ser B (Methodol)"},{"key":"85_CR5","doi-asserted-by":"crossref","first-page":"rs3","DOI":"10.1126\/scisignal.2001034","volume":"3","author":"A Bensimon","year":"2010","unstructured":"Bensimon A, Schmidt A, Ziv Y, Elkon R, Wang SY, Chen DJ, Aebersold R, Shiloh Y (2010) ATM-dependent and -independent dynamics of the nuclear phosphoproteome after DNA damage. Sci Signal 3:rs3","journal-title":"Sci Signal"},{"key":"85_CR6","doi-asserted-by":"crossref","first-page":"6575","DOI":"10.3390\/curroncol30070482","volume":"30","author":"JJ Biagi","year":"2023","unstructured":"Biagi JJ, Cosby R, Bahl M, Elfiki T, Goodwin R, Hallet J, Hirmiz K, Mahmud A (2023) Adjuvant chemotherapy and radiotherapy in resected pancreatic ductal adenocarcinoma: a systematic review and clinical practice guideline. Curr Oncol 30:6575\u20136586","journal-title":"Curr Oncol"},{"key":"85_CR7","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","volume":"66","author":"AN Blackford","year":"2017","unstructured":"Blackford AN, Jackson SP (2017) ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response. Mol Cell 66:801\u2013817","journal-title":"Mol Cell"},{"key":"85_CR8","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1744-7348.1939.tb06990.x","volume":"26","author":"CI Bliss","year":"1939","unstructured":"Bliss CI (1939) The toxicity of poisons applied jointly1. Ann Appl Biol 26:585\u2013615","journal-title":"Ann Appl Biol"},{"key":"85_CR9","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1200\/JCO.1997.15.6.2403","volume":"15","author":"HA Burris 3rd","year":"1997","unstructured":"Burris 3rd HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P et al (1997) Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 15:2403\u20132413","journal-title":"J Clin Oncol"},{"key":"85_CR10","first-page":"1081","volume":"39","author":"L Chen","year":"2018","unstructured":"Chen L, Zhou D, Liu Z, Huang X, Liu Q, Kang Y, Chen Z, Guo Y, Zhu H, Sun C (2018) Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway. Oncol Rep 39:1081\u20131089","journal-title":"Oncol Rep"},{"key":"85_CR11","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","volume":"9","author":"KA Cimprich","year":"2008","unstructured":"Cimprich KA, Cortez D (2008) ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 9:616\u2013627","journal-title":"Nat Rev Mol Cell Biol"},{"key":"85_CR12","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y, Adenis A, Raoul JL, Gourgou-Bourgade S, de la Fouchardiere C et al (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817\u20131825","journal-title":"N Engl J Med"},{"key":"85_CR13","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/nbt.1511","volume":"26","author":"J Cox","year":"2008","unstructured":"Cox J, Mann M (2008) MaxQuant enables high peptide identification rates, individualized p.p.b.-range mass accuracies and proteome-wide protein quantification. Nat Biotechnol 26:1367\u20131372","journal-title":"Nat Biotechnol"},{"key":"85_CR14","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41573-022-00558-5","volume":"22","author":"A da Costa","year":"2023","unstructured":"da Costa A, Chowdhury D, Shapiro GI, D\u2019Andrea AD, Konstantinopoulos PA (2023) Targeting replication stress in cancer therapy. Nat Rev Drug Discov 22:38\u201358","journal-title":"Nat Rev Drug Discov"},{"key":"85_CR15","doi-asserted-by":"crossref","first-page":"3946","DOI":"10.3390\/cancers13163946","volume":"13","author":"L De Lellis","year":"2021","unstructured":"De Lellis L, Veschi S, Tinari N, Mokini Z, Carradori S, Brocco D, Florio R, Grassadonia A, Cama A (2021) Drug repurposing, an attractive strategy in pancreatic cancer treatment: preclinical and clinical updates. Cancers 13:3946","journal-title":"Cancers"},{"key":"85_CR16","doi-asserted-by":"crossref","first-page":"D1539","DOI":"10.1093\/nar\/gkac1040","volume":"51","author":"EW Deutsch","year":"2023","unstructured":"Deutsch EW, Bandeira N, Perez-Riverol Y, Sharma V, Carver JJ, Mendoza L, Kundu DJ, Wang S, Bandla C, Kamatchinathan S et al (2023) The ProteomeXchange consortium at 10 years: 2023 update. Nucleic Acids Res 51:D1539\u2013D1548","journal-title":"Nucleic Acids Res"},{"key":"85_CR17","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1038\/bjc.2014.215","volume":"111","author":"S Eser","year":"2014","unstructured":"Eser S, Schnieke A, Schneider G, Saur D (2014) Oncogenic KRAS signalling in pancreatic cancer. Br J Cancer 111:817\u2013822","journal-title":"Br J Cancer"},{"key":"85_CR18","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/s43018-021-00326-1","volume":"3","author":"C Falcomata","year":"2022","unstructured":"Falcomata C, Barthel S, Widholz SA, Schneeweis C, Montero JJ, Toska A, Mir J, Kaltenbacher T, Heetmeyer J, Swietlik JJ et al (2022) Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Nat Cancer 3:318\u2013336","journal-title":"Nat Cancer"},{"key":"85_CR19","doi-asserted-by":"crossref","first-page":"571","DOI":"10.4251\/wjgo.v15.i4.571","volume":"15","author":"YT Fang","year":"2023","unstructured":"Fang YT, Yang WW, Niu YR, Sun YK (2023) Recent advances in targeted therapy for pancreatic adenocarcinoma. World J Gastrointest Oncol 15:571\u2013595","journal-title":"World J Gastrointest Oncol"},{"key":"85_CR20","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s11538-021-00868-6","volume":"83","author":"EA Fedak","year":"2021","unstructured":"Fedak EA, Adler FR, Abegglen LM, Schiffman JD (2021) ATM and ATR activation through crosstalk between DNA damage response pathways. Bull Math Biol 83:38","journal-title":"Bull Math Biol"},{"key":"85_CR21","doi-asserted-by":"crossref","first-page":"147","DOI":"10.3892\/ijo.2014.2418","volume":"45","author":"T Fujitomo","year":"2014","unstructured":"Fujitomo T, Daigo Y, Matsuda K, Ueda K, Nakamura Y (2014) Identification of a nuclear protein, LRRC42, involved in lung carcinogenesis. Int J Oncol 45:147\u2013156","journal-title":"Int J Oncol"},{"key":"85_CR22","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/jcm10040566","volume":"10","author":"A Garcia-Sampedro","year":"2021","unstructured":"Garcia-Sampedro A, Gaggia G, Ney A, Mahamed I, Acedo P (2021) The state-of-the-art of phase II\/III clinical trials for targeted pancreatic cancer therapies. J Clin Med 10:566","journal-title":"J Clin Med"},{"key":"85_CR23","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2022.100238","volume":"21","author":"F Hamood","year":"2022","unstructured":"Hamood F, Bayer FP, Wilhelm M, Kuster B, The M (2022) SIMSI-transfer: software-assisted reduction of missing values in phosphoproteomic and proteomic isobaric labeling data using tandem mass spectrum clustering. Mol Cell Proteom 21:100238","journal-title":"Mol Cell Proteom"},{"key":"85_CR24","doi-asserted-by":"crossref","first-page":"D512","DOI":"10.1093\/nar\/gku1267","volume":"43","author":"PV Hornbeck","year":"2015","unstructured":"Hornbeck PV, Zhang B, Murray B, Kornhauser JM, Latham V, Skrzypek E (2015) PhosphoSitePlus, 2014: mutations, PTMs and recalibrations. Nucleic Acids Res 43:D512\u2013D520","journal-title":"Nucleic Acids Res"},{"key":"85_CR25","first-page":"6110","volume":"51","author":"P Huang","year":"1991","unstructured":"Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2\u2032,2\u2032-difluorodeoxycytidine on DNA synthesis1. Cancer Res 51:6110\u20136117","journal-title":"Cancer Res"},{"key":"85_CR26","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/s41596-018-0082-x","volume":"14","author":"CS Hughes","year":"2019","unstructured":"Hughes CS, Moggridge S, Muller T, Sorensen PH, Morin GB, Krijgsveld J (2019) Single-pot, solid-phase-enhanced sample preparation for proteomics experiments. Nat Protoc 14:68\u201385","journal-title":"Nat Protoc"},{"key":"85_CR27","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41586-022-04437-2","volume":"603","author":"P Jaaks","year":"2022","unstructured":"Jaaks P, Coker EA, Vis DJ, Edwards O, Carpenter EF, Leto SM, Dwane L, Sassi F, Lightfoot H, Barthorpe S et al (2022) Effective drug combinations in breast, colon and pancreatic cancer cells. Nature 603:166\u2013173","journal-title":"Nature"},{"key":"85_CR28","volume":"2","author":"R Jadav","year":"2024","unstructured":"Jadav R, Weiland F, Noordermeer SM, Carroll T, Gao Y, Wang J, Zhou H, Lamoliatte F, Toth R, Macartney T et al (2024) Chemo-phosphoproteomic profiling with ATR inhibitors berzosertib and gartisertib uncovers new biomarkers and DNA damage response regulators. Mol Cell Proteom 2:100802","journal-title":"Mol Cell Proteom"},{"key":"85_CR29","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1093\/jnci\/djs491","volume":"105","author":"A Jemal","year":"2013","unstructured":"Jemal A, Simard EP, Dorell C, Noone AM, Markowitz LE, Kohler B, Eheman C, Saraiya M, Bandi P, Saslow D et al (2013) Annual Report to the Nation on the Status of Cancer, 1975\u20132009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 105:175\u2013201","journal-title":"J Natl Cancer Inst"},{"key":"85_CR30","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1126\/science.1164368","volume":"321","author":"S Jones","year":"2008","unstructured":"Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A et al (2008) Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321:1801\u20131806","journal-title":"Science"},{"key":"85_CR31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1007\/s10637-018-0598-5","volume":"36","author":"J Kang","year":"2018","unstructured":"Kang J, Hwang I, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Seo DW et al (2018) Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Invest N. Drugs 36:732\u2013741","journal-title":"Invest N. Drugs"},{"key":"85_CR32","first-page":"83","volume":"2","author":"RK Kelley","year":"2008","unstructured":"Kelley RK, Ko AH (2008) Erlotinib in the treatment of advanced pancreatic cancer. Biologics 2:83\u201395","journal-title":"Biologics"},{"key":"85_CR33","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1002\/mc.20221","volume":"45","author":"JE Kim","year":"2006","unstructured":"Kim JE, Minter-Dykhouse K, Chen J (2006) Signaling networks controlled by the MRN complex and MDC1 during early DNA damage responses. Mol Carcinog 45:403\u2013408","journal-title":"Mol Carcinog"},{"key":"85_CR34","doi-asserted-by":"crossref","first-page":"37538","DOI":"10.1074\/jbc.274.53.37538","volume":"274","author":"ST Kim","year":"1999","unstructured":"Kim ST, Lim DS, Canman CE, Kastan MB (1999) Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem 274:37538\u201337543","journal-title":"J Biol Chem"},{"key":"85_CR35","unstructured":"Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C et al (2017a) ProteomeXchange PXD005336 (https:\/\/proteomecentral.proteomexchange.org\/cgi\/GetDataset?ID=PXD005336) [DATASET]"},{"key":"85_CR36","doi-asserted-by":"crossref","first-page":"eaan4368","DOI":"10.1126\/science.aan4368","volume":"358","author":"S Klaeger","year":"2017","unstructured":"Klaeger S, Heinzlmeir S, Wilhelm M, Polzer H, Vick B, Koenig PA, Reinecke M, Ruprecht B, Petzoldt S, Meng C et al (2017b) The target landscape of clinical kinase drugs. Science 358:eaan4368","journal-title":"Science"},{"key":"85_CR37","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.cell.2005.12.041","volume":"124","author":"A Kumagai","year":"2006","unstructured":"Kumagai A, Lee J, Yoo HY, Dunphy WG (2006) TopBP1 activates the ATR-ATRIP complex. Cell 124:943\u2013955","journal-title":"Cell"},{"key":"85_CR38","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112721","volume":"42","author":"M Kupculak","year":"2023","unstructured":"Kupculak M, Bai F, Luo Q, Yoshikawa Y, Lopez-Martinez D, Xu H, Uphoff S, Cohn MA (2023) Phosphorylation by ATR triggers FANCD2 chromatin loading and activates the Fanconi anemia pathway. Cell Rep 42:112721","journal-title":"Cell Rep"},{"key":"85_CR39","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/nar\/gkv1312","volume":"44","author":"DH Larsen","year":"2016","unstructured":"Larsen DH, Stucki M (2016) Nucleolar responses to DNA double-strand breaks. Nucleic Acids Res 44:538\u2013544","journal-title":"Nucleic Acids Res"},{"key":"85_CR40","doi-asserted-by":"crossref","first-page":"D1541","DOI":"10.1093\/nar\/gkab1026","volume":"50","author":"L Lautenbacher","year":"2022","unstructured":"Lautenbacher L, Samaras P, Muller J, Grafberger A, Shraideh M, Rank J, Fuchs ST, Schmidt TK, The M, Dallago C et al (2022) ProteomicsDB: toward a FAIR open-source resource for life-science research. Nucleic Acids Res 50:D1541\u2013D1552","journal-title":"Nucleic Acids Res"},{"key":"85_CR41","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1159\/000453257","volume":"94","author":"N Le","year":"2016","unstructured":"Le N, Vinci A, Schober M, Krug S, Javed MA, Kohlmann T, Sund M, Neesse A, Beyer G (2016) Real-world clinical practice of intensified chemotherapies for metastatic pancreatic cancer: results from a pan-European questionnaire study. Digestion 94:222\u2013229","journal-title":"Digestion"},{"key":"85_CR42","first-page":"28","volume":"20","author":"CY Lee","year":"2024","unstructured":"Lee CY, The M, Meng C, Bayer FP, Putzker K, Muller J, Streubel J, Woortman J, Sakhteman A, Resch M et al (2024) Illuminating phenotypic drug responses of sarcoma cells to kinase inhibitors by phosphoproteomics. Mol Syst Biol 20:28\u201355","journal-title":"Mol Syst Biol"},{"key":"85_CR43","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1124\/jpet.118.255786","volume":"370","author":"F Lei","year":"2019","unstructured":"Lei F, Xi X, Batra SK, Bronich TK (2019) Combination therapies and drug delivery platforms in combating pancreatic cancer. J Pharm Exp Ther 370:682\u2013694","journal-title":"J Pharm Exp Ther"},{"key":"85_CR44","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1021\/pr301073j","volume":"12","author":"S Lemeer","year":"2013","unstructured":"Lemeer S, Zorgiebel C, Ruprecht B, Kohl K, Kuster B (2013) Comparing immobilized kinase inhibitors and covalent ATP probes for proteomic profiling of kinase expression and drug selectivity. J Proteome Res 12:1723\u20131731","journal-title":"J Proteome Res"},{"key":"85_CR45","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.3892\/or.2017.5580","volume":"37","author":"S Liu","year":"2017","unstructured":"Liu S, Ge Y, Wang T, Edwards H, Ren Q, Jiang Y, Quan C, Wang G (2017) Inhibition of ATR potentiates the cytotoxic effect of gemcitabine on pancreatic cancer cells through enhancement of DNA damage and abrogation of ribonucleotide reductase induction by gemcitabine. Oncol Rep 37:3377\u20133386","journal-title":"Oncol Rep"},{"key":"85_CR46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1038\/nrclinonc.2016.96","volume":"14","author":"JS Lopez","year":"2017","unstructured":"Lopez JS, Banerji U (2017) Combine and conquer: challenges for targeted therapy combinations in early phase trials. Nat Rev Clin Oncol 14:57\u201366","journal-title":"Nat Rev Clin Oncol"},{"key":"85_CR47","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1126\/science.1140321","volume":"316","author":"S Matsuoka","year":"2007","unstructured":"Matsuoka S, Ballif BA, Smogorzewska A, McDonald 3rd ER, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y et al (2007) ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 316:1160\u20131166","journal-title":"Science"},{"key":"85_CR48","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1038\/s41416-021-01405-x","volume":"125","author":"MR Middleton","year":"2021","unstructured":"Middleton MR, Dean E, Evans TRJ, Shapiro GI, Pollard J, Hendriks BS, Falk M, Diaz-Padilla I, Plummer R (2021) Phase 1 study of the ATR inhibitor berzosertib (formerly M6620, VX-970) combined with gemcitabine +\/- cisplatin in patients with advanced solid tumours. Br J Cancer 125:510\u2013519","journal-title":"Br J Cancer"},{"key":"85_CR49","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1158\/0008-5472.CAN-12-1453","volume":"73","author":"K Miyabayashi","year":"2013","unstructured":"Miyabayashi K, Ijichi H, Mohri D, Tada M, Yamamoto K, Asaoka Y, Ikenoue T, Tateishi K, Nakai Y, Isayama H et al (2013) Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals. Cancer Res 73:2221\u20132234","journal-title":"Cancer Res"},{"key":"85_CR50","doi-asserted-by":"crossref","DOI":"10.1186\/s12920-020-00778-x","volume":"13","author":"L Moody","year":"2020","unstructured":"Moody L, Chen H, Pan YX (2020) Considerations for feature selection using gene pairs and applications in large-scale dataset integration, novel oncogene discovery, and interpretable cancer screening. BMC Med Genomics 13:148","journal-title":"BMC Med Genomics"},{"key":"85_CR51","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2006.07.9525","volume":"25","author":"MJ Moore","year":"2007","unstructured":"Moore MJ, Goldstein D, Hamm J, Figer A, Hecht JR, Gallinger S, Au HJ, Murawa P, Walde D, Wolff RA et al (2007) Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960\u20131966","journal-title":"J Clin Oncol"},{"key":"85_CR52","doi-asserted-by":"crossref","first-page":"17330","DOI":"10.1074\/jbc.C700079200","volume":"282","author":"JJ Mu","year":"2007","unstructured":"Mu JJ, Wang Y, Luo H, Leng M, Zhang J, Yang T, Besusso D, Jung SY, Qin J (2007) A proteomic analysis of ataxia telangiectasia-mutated (ATM)\/ATM-Rad3-related (ATR) substrates identifies the ubiquitin-proteasome system as a regulator for DNA damage checkpoints. J Biol Chem 282:17330\u201317334","journal-title":"J Biol Chem"},{"key":"85_CR53","doi-asserted-by":"publisher","unstructured":"M\u00fcller J, Bayer FP, Wilhelm M, Schuh MG, Kuster B, The M (2025) PTMNavigator: interactive visualization of differentially regulated post-translational modifications in cellular signaling pathways. Nat Commun 16:510. https:\/\/doi.org\/10.1038\/s41467-024-55533-y","DOI":"10.1038\/s41467-024-55533-y"},{"key":"85_CR54","volume":"14","author":"NU Nair","year":"2023","unstructured":"Nair NU, Greninger P, Zhang X, Friedman AA, Amzallag A, Cortez E, Sahu AD, Lee JS, Dastur A, Egan RK et al (2023) A landscape of response to drug combinations in non-small cell lung cancer. Nat Commun 14:3830","journal-title":"Nat Commun"},{"key":"85_CR55","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/emboj\/16.3.545","volume":"16","author":"MJ O\u2019Connell","year":"1997","unstructured":"O\u2019Connell MJ, Raleigh JM, Verkade HM, Nurse P (1997) Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 16:545\u2013554","journal-title":"EMBO J"},{"key":"85_CR56","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1158\/1535-7163.MCT-15-0843","volume":"15","author":"J O\u2019Neil","year":"2016","unstructured":"O\u2019Neil J, Benita Y, Feldman I, Chenard M, Roberts B, Liu Y, Li J, Kral A, Lejnine S, Loboda A et al (2016) An unbiased oncology compound screen to identify novel combination strategies. Mol Cancer Ther 15:1155\u20131162","journal-title":"Mol Cancer Ther"},{"key":"85_CR57","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM (2021) Pancreatic cancer: a review. JAMA 326:851\u2013862","journal-title":"JAMA"},{"key":"85_CR58","first-page":"3","volume":"22","author":"W Plunkett","year":"1995","unstructured":"Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R, Gandhi V (1995) Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22:3\u201310","journal-title":"Semin Oncol"},{"key":"85_CR59","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/s41589-023-01459-3","volume":"20","author":"M Reinecke","year":"2023","unstructured":"Reinecke M, Brear P, Vornholz L, Berger BT, Seefried F, Wilhelm S, Samaras P, Gyenis L, Litchfield DW, Medard G et al (2023a) Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors. Nat Chem Biol 20:577\u2013585","journal-title":"Nat Chem Biol"},{"key":"85_CR60","unstructured":"Reinecke M, Brear P, Vornholz L, Berger BT, Seefried F, Wilhelm S, Samaras P, Gyenis L, Litchfield DW, Medard G et al (2023b) ProteomeXchange PXD043230 (https:\/\/proteomecentral.proteomexchange.org\/cgi\/GetDataset?ID=PXD043230) [DATASET]"},{"key":"85_CR61","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1021\/acschembio.8b01020","volume":"14","author":"M Reinecke","year":"2019","unstructured":"Reinecke M, Ruprecht B, Poser S, Wiechmann S, Wilhelm M, Heinzlmeir S, Kuster B, Medard G (2019) Chemoproteomic selectivity profiling of PIKK and PI3K kinase inhibitors. ACS Chem Biol 14:655\u2013664","journal-title":"ACS Chem Biol"},{"key":"85_CR62","doi-asserted-by":"crossref","first-page":"e0146021","DOI":"10.1371\/journal.pone.0146021","volume":"10","author":"C Ritz","year":"2015","unstructured":"Ritz C, Baty F, Streibig JC, Gerhard D (2015) Dose-response analysis using R. PLoS ONE 10:e0146021","journal-title":"PLoS ONE"},{"key":"85_CR63","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","volume":"273","author":"EP Rogakou","year":"1998","unstructured":"Rogakou EP, Pilch DR, Orr AH, Ivanova VS, Bonner WM (1998) DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 273:5858\u20135868","journal-title":"J Biol Chem"},{"key":"85_CR64","first-page":"7","volume":"71","author":"RL Siegel","year":"2021","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer Statistics, 2021. CA Cancer J Clin 71:7\u201333","journal-title":"CA Cancer J Clin"},{"key":"85_CR65","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-020-58290-2","volume":"10","author":"M Sinkala","year":"2020","unstructured":"Sinkala M, Mulder N, Martin D (2020) Machine learning and network analyses reveal disease subtypes of pancreatic cancer and their molecular characteristics. Sci Rep 10:1212","journal-title":"Sci Rep"},{"key":"85_CR66","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2017.72.6463","volume":"35","author":"M Sinn","year":"2017","unstructured":"Sinn M, Bahra M, Liersch T, Gellert K, Messmann H, Bechstein W, Waldschmidt D, Jacobasch L, Wilhelm M, Rau BM et al (2017) CONKO-005: adjuvant chemotherapy with gemcitabine plus erlotinib versus gemcitabine alone in patients after R0 resection of pancreatic cancer: a multicenter randomized phase III trial. J Clin Oncol 35:3330\u20133337","journal-title":"J Clin Oncol"},{"key":"85_CR67","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.dnarep.2006.01.012","volume":"5","author":"M Stucki","year":"2006","unstructured":"Stucki M, Jackson SP (2006) gammaH2AX and MDC1: anchoring the DNA-damage-response machinery to broken chromosomes. DNA Repair 5:534\u2013543","journal-title":"DNA Repair"},{"key":"85_CR68","volume":"4","author":"H Sun","year":"2014","unstructured":"Sun H, Ma H, Hong G, Sun H, Wang J (2014) Survival improvement in patients with pancreatic cancer by decade: A period analysis of the SEER database, 1981\u20132010. Sci Rep 4:6747","journal-title":"Sci Rep"},{"key":"85_CR69","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/nature01125","volume":"420","author":"H Tauchi","year":"2002","unstructured":"Tauchi H, Kobayashi J, Morishima K, van Gent DC, Shiraishi T, Verkaik NS, vanHeems D, Ito E, Nakamura A, Sonoda E et al (2002) Nbs1 is essential for DNA repair by homologous recombination in higher vertebrate cells. Nature 420:93\u201398","journal-title":"Nature"},{"key":"85_CR70","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1101\/gad.851000","volume":"14","author":"RS Tibbetts","year":"2000","unstructured":"Tibbetts RS, Cortez D, Brumbaugh KM, Scully R, Livingston D, Elledge SJ, Abraham RT (2000) Functional interactions between BRCA1 and the checkpoint kinase ATR during genotoxic stress. Genes Dev 14:2989\u20133002","journal-title":"Genes Dev"},{"key":"85_CR71","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova S, Temu T, Sinitcyn P, Carlson A, Hein MY, Geiger T, Mann M, Cox J (2016) The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat Methods 13:731\u2013740","journal-title":"Nat Methods"},{"key":"85_CR72","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.surg.2006.09.009","volume":"141","author":"CW Tzeng","year":"2007","unstructured":"Tzeng CW, Frolov A, Frolova N, Jhala NC, Howard JH, Buchsbaum DJ, Vickers SM, Heslin MJ, Arnoletti JP (2007) Epidermal growth factor receptor (EGFR) is highly conserved in pancreatic cancer. Surgery 141:464\u2013469","journal-title":"Surgery"},{"key":"85_CR75","doi-asserted-by":"crossref","first-page":"112581","DOI":"10.1016\/j.celrep.2023.112581","volume":"42","author":"A Vall\u00e9s-Mart\u00ed","year":"2023","unstructured":"Vall\u00e9s-Mart\u00ed A, Mantini G, Manoukian P, Waasdorp C, Sarasqueta AF, de Goeij-de Haas RR, Henneman AA, Piersma SR, Pham TV, Knol JC et al (2023) Phosphoproteomics guides effective low-dose drug combinations against pancreatic ductal adenocarcinoma. Cell Rep 42:112581","journal-title":"Cell Rep"},{"key":"85_CR76","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","volume":"518","author":"N Waddell","year":"2015","unstructured":"Waddell N, Pajic M, Patch AM, Chang DK, Kassahn KS, Bailey P, Johns AL, Miller D, Nones K, Quek K et al (2015) Whole genomes redefine the mutational landscape of pancreatic cancer. Nature 518:495\u2013501","journal-title":"Nature"},{"key":"85_CR77","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1158\/1535-7163.MCT-18-0010","volume":"17","author":"Y Wallez","year":"2018","unstructured":"Wallez Y, Dunlop CR, Johnson TI, Koh SB, Fornari C, Yates JWT, Bernaldo de Quiros Fernandez S, Lau A, Richards FM, Jodrell DI (2018) The ATR inhibitor AZD6738 synergizes with gemcitabine in vitro and in vivo to induce pancreatic ductal adenocarcinoma regression. Mol Cancer Ther 17:1670\u20131682","journal-title":"Mol Cancer Ther"},{"key":"85_CR78","doi-asserted-by":"crossref","first-page":"6647","DOI":"10.1158\/0008-5472.CAN-07-0924","volume":"67","author":"J Yan","year":"2007","unstructured":"Yan J, Kim YS, Yang XP, Li LP, Liao G, Xia F, Jetten AM (2007) The ubiquitin-interacting motif containing protein RAP80 interacts with BRCA1 and functions in DNA damage repair response. Cancer Res 67:6647\u20136656","journal-title":"Cancer Res"},{"key":"85_CR79","doi-asserted-by":"crossref","first-page":"eade3925","DOI":"10.1126\/science.ade3925","volume":"380","author":"J Zecha","year":"2023","unstructured":"Zecha J, Bayer FP, Wiechmann S, Woortman J, Berner N, Muller J, Schneider A, Kramer K, Abril-Gil M, Hopf T et al (2023) Decrypting drug actions and protein modifications by dose- and time-resolved proteomics. Science 380:eade3925","journal-title":"Science"},{"key":"85_CR80","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1074\/mcp.RA120.002164","volume":"19","author":"J Zecha","year":"2020","unstructured":"Zecha J, Lee CY, Bayer FP, Meng C, Grass V, Zerweck J, Schnatbaum K, Michler T, Pichlmair A, Ludwig C et al (2020) Data, reagents, assays and merits of proteomics for SARS-CoV-2 research and testing. Mol Cell Proteom 19:1503\u20131522","journal-title":"Mol Cell Proteom"},{"key":"85_CR81","doi-asserted-by":"crossref","first-page":"4504","DOI":"10.3390\/ijms20184504","volume":"20","author":"S Zeng","year":"2019","unstructured":"Zeng S, Pottler M, Lan B, Grutzmann R, Pilarsky C, Yang H (2019) Chemoresistance in pancreatic cancer. Int J Mol Sci 20:4504","journal-title":"Int J Mol Sci"},{"key":"85_CR82","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1158\/1538-7445.AM2019-369","volume":"79","author":"FT Zenke","year":"2019","unstructured":"Zenke FT, Zimmermann A, Dahmen H, Elenbaas B, Pollard J, Reaper P, Bagrodia S, Spilker ME, Amendt C, Blaukat A (2019) Antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy. Cancer Res 79:369","journal-title":"Cancer Res"},{"key":"85_CR83","volume":"14","author":"H Zhang","year":"2023","unstructured":"Zhang H, Kreis J, Schelhorn SE, Dahmen H, Grombacher T, Zuhlsdorf M, Zenke FT, Guan Y (2023) Mapping combinatorial drug effects to DNA damage response kinase inhibitors. Nat Commun 14:8310","journal-title":"Nat Commun"},{"key":"85_CR84","doi-asserted-by":"crossref","first-page":"4129","DOI":"10.1128\/MCB.21.13.4129-4139.2001","volume":"21","author":"H Zhao","year":"2001","unstructured":"Zhao H, Piwnica-Worms H (2001) ATR-mediated checkpoint pathways regulate phosphorylation and activation of human Chk1. Mol Cell Biol 21:4129\u20134139","journal-title":"Mol Cell Biol"}],"container-title":["Molecular Systems Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44320-025-00085-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1038\/s44320-025-00085-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1038\/s44320-025-00085-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T09:54:03Z","timestamp":1786960443000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1038\/s44320-025-00085-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,21]]},"references-count":82,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2025,3,3]]}},"alternative-id":["85"],"URL":"https:\/\/doi.org\/10.1038\/s44320-025-00085-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.03.22.586243","asserted-by":"object"}]},"ISSN":["1744-4292"],"issn-type":[{"value":"1744-4292","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,21]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BK is co-founder and shareholder of OmicScouts and MSAID. He has no operational role in either company. JTS receives honoraria as consultant or for continuing medical education presentations from AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Immunocore, MSD Sharp Dohme, Novartis, Roche\/Genentech, and Servier. His institution receives research funding from Abalos Therapeutics, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Eisbach Bio, and Roche\/Genentech; he holds ownership in FAPI Holding (<\u00a03%); all outside the submitted work. HS received travel support from Servier, with no financial benefit and outside the submitted work. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure and competing interests statement"}}],"article-number":"3"}}